Windlas Biotech profit and loss

Latest FY26

Revenue: ₹904cr+19.0% on FY25
EBITDA: ₹105cr+11.2% on FY25
Net profit: ₹66.4cr+9.5% on FY25
EPS: ₹31.59+8.8% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	942	904	760	631	513	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	17.7	17.8	17.6	13.5	10.0
	960	922	778	644	523
	−7.1	12.5	2.3	3.0	−0.8
	601	538	491	384	341
	−13.2	7.1	−21.5	9.6	−15.3
	164	152	123	87.5	70.3
	5.4	4.8	4.4	1.1	0.8
	30.5	30.7	28.0	13.4	12.4
	92.7	90.1	71.0	69.2	57.1
	873	835	698	567	466
	105	105	94.1	78.1	60.2
	74.3	74.0	66.1	64.7	47.9
Profit
	86.6	86.9	79.4	77.0	57.1
	86.6	86.9	79.4	77.0	57.1
	21.5	20.7	18.3	17.3	14.4
	−1.3	−0.2	0.5	1.5	0.1
	20.2	20.5	18.7	18.9	14.4
	66.4	66.4	60.6	58.1	42.6
	66.4	66.4	60.6	58.1	42.6
	0.0	0.1	−0.5	−0.2	−0.2
	66.5	66.5	60.1	57.9	42.5
Per share
	₹31.63	₹31.59	₹29.03	₹27.95	₹19.71
	₹31.25	₹31.14	₹28.71	₹27.86	₹19.71
Other comprehensive income — detail
	0.0	0.1	−0.5	—	—
	0.0	0.1	−0.7	−0.3	−0.2
	0.0	0.0	−0.2	—	—
	—	—	—	−0.1	−0.1
Per share — as-filed variants
	₹31.63	₹31.59	₹29.03	₹27.95	₹19.71
	₹31.25	₹31.14	₹28.71	₹27.86	₹19.71
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	362	347	288	235	188
	38.4%	38.4%	37.9%	37.2%	36.6%
Adjusted (ex-exceptional items) — derived
	86.6	86.9	79.4	77.0	57.1
	66.4	66.4	60.6	58.1	42.6
	₹31.63	₹31.59	₹29.03	₹27.95	₹19.71

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

WINDLAS₹888.70

Windlas Biotech Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersHESTERBIO INDOCO SAIPARENT SYNCOMF PANACEABIO NGLFINE HIKAL JAGSNPHARMMcap ₹1,876 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	513.1	631.0	759.9	904.1	942.1
Other Income	10.0	13.5	17.6	17.8	17.7
Total Income	523.0	644.4	777.5	921.9	959.8
Expenses
+ Cost of Materials Consumed	-0.8	3.0	2.3	12.5	-7.1
+ Purchases of Stock-in-Trade	341.5	383.6	491.1	537.7	600.5
+ Changes in Inventories	-15.3	9.6	-21.5	7.1	-13.2
+ Employee Benefit Expense	70.3	87.5	122.9	152.1	164.3
+ Finance Costs	0.8	1.1	4.4	4.8	5.4
+ Depreciation & Amortisation	12.4	13.4	28.0	30.7	30.5
+ Other Expenses	57.1	69.2	71.0	90.1	92.7
Total Expenses	466.0	567.4	698.1	835.0	873.2
EBITDA	60.2	78.1	94.1	104.7	104.9
EBIT	47.9	64.7	66.1	74.0	74.3
Profit
PBT before Exceptional Items	57.1	77.0	79.4	86.9	86.6
Pretax Income	57.1	77.0	79.4	86.9	86.6
+ Current Tax	14.4	17.3	18.3	20.7	21.5
+ Deferred Tax	0.1	1.5	0.5	-0.2	-1.3
Tax Expense	14.4	18.9	18.7	20.5	20.2
Net Income	42.6	58.1	60.6	66.4	66.4
+ Net Income — Continuing Ops	42.6	58.1	60.6	66.4	66.4
+ Other Comprehensive Income	-0.2	-0.2	-0.5	0.1	0.0
Total Comprehensive Income	42.5	57.9	60.1	66.5	66.5
Per Share
Basic EPS	19.71	27.95	29.03	31.59	31.63
Diluted EPS	19.71	27.86	28.71	31.14	31.25
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-0.5	0.1	0.0
+ Items NOT to be Reclassified to P&L	-0.2	-0.3	-0.7	0.1	0.0
+ Tax on Items NOT to be Reclassified	—	—	-0.2	0.0	0.0
+ Tax on Items NOT to be Reclassified — alt tag	-0.1	-0.1	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	19.71	27.95	29.03	31.59	31.63
Diluted EPS — Continuing Operations	19.71	27.86	28.71	31.14	31.25
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	187.6	234.8	288.0	346.9	361.9
Gross Margin %	36.57	37.21	37.90	38.37	38.41
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	57.1	77.0	79.4	86.9	86.6
Net Income Adj (tax-effected)	42.6	58.1	60.6	66.4	66.4
EPS Adj	19.71	27.95	29.03	31.59	31.63
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	5.00	5.00	5.00	5.00
Paid Up Equity Capital	10.5	10.4	10.5	10.6	10.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.